Galderma has announced that the U.S. Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5%) for over-the-counter (OTC) use in individuals aged 12 years and older. This Prescription-to-OTC transition significantly expands public access to a dual-action, prescription-strength therapeutic that has been a standard in clinical dermatology for over 15 years.
This milestone integrates Galderma’s therapeutic innovations into its consumer skincare portfolio, expanding the reach of a clinically backed regimen that previously required a prescription.
Differin Epiduo addresses the multi-factorial nature of acne vulgaris by combining two complementary mechanisms of action into a single, stable formulation. Rather than relying on a monotherapy, this fixed-dose combination targets separate biological drivers of acne simultaneously:
By pairing these actives, the formulation treats both inflammatory and non-inflammatory lesions more effectively than either active ingredient utilized independently.
The FDA approval is supported by an extensive clinical research program involving multiple randomized, controlled Phase 3 studies, encompassing over 3,200 patients globally.
The clinical data demonstrated consistent efficacy and a favorable safety profile across diverse skin tones and patient populations:
| Clinical Metric | Observed Outcome |
| Onset of Action | Antimicrobial activity initiates on Day 1; clinically meaningful lesion reduction observed by Week 1 |
| Short-Term Efficacy | Up to a 70.3% reduction in inflammatory acne lesions at Week 12 |
| Long-Term Control | Sustained efficacy with an approximate 65% total lesion reduction maintained through 12 months of continuous use |
| Comparative Success | Consistently outperformed monotherapies (adapalene alone or benzoyl peroxide alone) and vehicle gels in Investigator Global Assessment (IGA) success rates |
“Differin Epiduo pairs two complementary, evidence‑based actives... This retinoid-benzoyl peroxide combination aligns with dermatology guidelines, which strongly recommend using both together as a first‑line, multimodal approach to acne treatment.”
— Bill Andriopoulos, Ph.D., Head of Global Medical Affairs at Galderma
A key technical element of the formulation is its Simulgel™ Gel Base. Retinoids and benzoyl peroxide are traditionally difficult to stabilize together in a single vehicle, often requiring separate applications to prevent degradation or severe skin irritation.
The Simulgel base resolves these challenges by:
This vehicle delivery system consolidates treatment into a once-daily, single-pump application, directly addressing a major barrier in acne therapy: patient compliance. Simplified regimens are clinically proven to foster consistent daily use, resulting in superior long-term outcomes.
Differin Epiduo is scheduled to become available over-the-counter at major U.S. mass retailers—including Walmart, Target, Ulta, and Amazon—beginning in the summer of 2026.
This transition allows individuals with moderate-to-severe acne to autonomously implement a first-line clinical treatment protocol. (Note: Outside of the United States, Epiduo remains classified strictly as a prescription-only medication).
Click HERE to read more
Elevate-Derm Alliance Editorial Committee